Selvita Licenses Cresset’s Computational Tools for SAR Analysis & Ligand-Based Design
Cresset, innovative provider of computational chemistry software and services, is pleased to announce that Selvita S.A., a drug discovery company located in Krakow, Poland, has licensed Cresset’s Forge and Spark.These applications provide extensive capabilities in SAR analysis, ligand-based molecular design, and bioisosteric replacement.
Dr. Mariusz Milik, Head of Computational Chemistry at Selvita, says “We are currently focused on target based design; however, as requirements of our projects change, we need to include ligand-based approaches in the methods we use. We anticipate using Cresset’s software as a key component in our discovery chemistry capabilities.”
“At Cresset, we are delighted to see growth in the emerging drug discovery market of Central and Eastern Europe,” adds Dr. David Bardsley, Cresset’s Commercial Director. “Both Forge and Spark will enhance Selvita’s chemistry capabilities.The Spark reagent databases will enable them to inform synthetic decisions, whilst Forge will give control and insight into their activity data, enabling them to plan the direction of their projects with confidence.”
Cresset develops software for calculating and comparing the molecular field characteristics of chemical compounds. Cresset also offers consultancy services that enable companies to outsource computational chemistry work to achieve high value, on-demand expertise, particularly in the areas of library design, virtual screening, scaffold hopping, lead optimization and patent analysis.
Cresset’s field technology uses the surface properties of molecules to evaluate their activities and properties, rather than relying on 2D structure similarity, which enables Cresset’s users to find more interesting, novel, and relevant results than other methods. This field technology provides a smarter, structure independent way of hit-finding, lead switching and lead optimization in drug discovery and other chemistry-based research projects. Cresset’s field technologies have been successfully applied to a very wide range of target classes, with and without structural information, on over 100 projects for major pharmaceutical and biotechnology companies. For more information, visit www.cresset-group.com.
Selvita is a Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat oncology, CNS, and autoimmune disorders, as well as provision of drug discovery services. It was established in 2007 and currently employs 200 people, including 63 PhDs. Selvita has currently several internal projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2015. The most advanced programs at Selvita are SEL24, a preclinical PIM/FLT3 kinase inhibitor, with multiple indications in hematopoietic tumors and SEL120, first-in-class small molecule inhibitor of cyclin dependent kinase CDK8. For more information, visit www.selvita.com.
Total Page Views: 900
